ClinicalTrials.gov
public full text
Public Domain
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy and safety of gepants in migraine management: a narrative review focusing on atogepant and rimegepant#1000632
- The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients#1086764
- Trigeminovascular Calcitonin Gene-Related Peptide Release and Peripheral Vascular Responses in a Mouse Model of Accelerated Aging: Implications for Migraine#4835
- Atogepant reduces triptan use: a pharmacoeconomic analysis in migraine prevention.#312477
- The Role of CGRPand Nociceptin in Migraine#1072645
Record · ID 1484813
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive